Obstetrics and Gynecology · Nov 17, 2026

The Rising Tide of Cardiovascular Risk in Younger Women

By Stuenkel CA

Menopause management is in the midst of a paradigm shift as enthusiasm, fueled by the lay press and online influencers, increases amongst women, yielding an escalating interest in hormone therapy (HT) that has not been experienced since the turn of the last century. Updates to regulatory labeling of menopausal HT products include the removal of boxed warnings and language that recommended using the lowest dose for the shortest time while focusing on risks and benefits to those seeking menopause symptom relief—women younger than 60 or within 10 years of menopause. This renewed desire for menopausal HT must be tempered with the understanding that risks for cardiovascular disease (CVD) are also rising in premenopausal women as are hospitalizations for acute coronary syndromes. Factors that contribute to long-term cardiovascular risk include adverse pregnancy outcomes, which are occurring with increasing frequency. The metabolic changes that accompany the menopause transition further complicate a woman's cardiovascular risk profile. Many women today will arrive at menopause with more advanced CVD risk than what was encountered in the past. If women are considering HT for menopausal symptom relief or bone preservation, careful consideration is required to identify and treat modifiable CVD risks—dyslipidemia, glucose intolerance, hypertension, and, increasingly, obesity—to targets established by guidelines before initiating HT. Risk assessment with validated risk calculators can help stratify CVD risk, a factor that determines lipid lowering therapy, and the advisability and choice of menopausal HT. The rising tide of cardiovascular risk does not have to make waves at menopause.

doi.org/10.1097/aog.0000000000006471PubMed 43044091Interventions

AgingResearch.News